Group 1 - The core announcement is that Sanofi Pharmaceutical (stock code: 2257) plans to raise approximately HKD 210 million through a general authorization to issue new shares, totaling 17,352,421 shares at a subscription price of HKD 12.00 per share, which represents a discount of about 19.8% compared to the closing price of HKD 14.97 on September 5, 2025 [1] - The subscription price is at a premium of approximately 1.6% compared to the average closing price of HKD 11.82 over the last five trading days prior to the subscription agreement date [1] - The newly issued shares will represent about 16.5% of the existing issued share capital of the company as of the announcement date, and approximately 14.2% of the enlarged issued share capital after the issuance [1] Group 2 - The funds raised will be used for general working capital purposes [1] - The completion of the subscription agreement A is subject to certain conditions and is expected to be finalized no later than November 7, 2025, while agreements B, C, and D are expected to be completed by December 7, 2025 [1] - Sanofi Pharmaceutical focuses on RNA therapy and aims to develop innovative drugs targeting unmet medical needs and significant market opportunities [1]